


ACL Laboratories COVID-19 and Influenza Activity Report

Updated: Dec 12, 2021



| RESPIRATORY PATHOGEN PANEL Dec 12, 2021 Positivity Rate (%) | | | | | | | | | | | | | | | | | | | | | | | |
|---|-------|--------------|-----------|------------|-------|-------|-------|---------|--------|--------|--------|--------|----------|----------|----------|----------|------|------|-------|------|-------------|------------|-------------|
| MONTH | FLU A | FLU A (H1N1) | 2009 H1N1 | FLU A H3N2 | FLU B | RSV A | RSV B | RSV A/B | PARA 1 | PARA 2 | PARA 3 | Para 4 | COR 229E | COR NL63 | COR OC43 | COR HKU1 | META | E/R | Adeno | BOCA | Legio nella | Chla mydia | Myco plasma |
| JAN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 7.1 | 0.7 | 0.3 | 0.0 | 0.0 | 0.0 | |
| FEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 0.0 | 0.0 | 0.2 | 6.1 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | |
| MAR | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.3 | 0.4 | 0.1 | 0.1 | 0.3 | 0.1 | 1.4 | 0.9 | 0.1 | 0.4 | 12.2 | 1.2 | 0.3 | 0.0 | 0.1 | 0.1 | |
| APR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.2 | 0.5 | 0.0 | 0.0 | 2.5 | 2.9 | 0.0 | 0.8 | 15.3 | 1.4 | 1.2 | 0.0 | 0.0 | 0.0 | |
| MAY | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.7 | 3.9 | 0.0 | 0.2 | 1.4 | 3.9 | 0.0 | 0.0 | 14.4 | 1.7 | 1.4 | 0.2 | 0.0 | 0.1 | |
| JUN | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 1.8 | 1.9 | 0.0 | 0.3 | 9.6 | 0.0 | 0.3 | 0.4 | 2.4 | 0.0 | 0.1 | 15.8 | 1.1 | 1.8 | 0.0 | 0.0 | 0.1 |
| JUL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 7.2 | 8.2 | 0.1 | 0.5 | 12.9 | 0.0 | 0.1 | 0.4 | 1.4 | 0.0 | 0.5 | 18.9 | 1.6 | 4.4 | 0.4 | 0.0 | 0.0 |
| AUG | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.8 | 12.5 | 13.3 | 0.0 | 1.2 | 6.2 | 0.1 | 0.1 | 0.1 | 0.5 | 0.0 | 0.7 | 14.0 | 1.3 | 3.6 | 0.0 | 0.0 | 0.0 |
| SEP | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 10.6 | 11.3 | 0.0 | 0.9 | 1.8 | 0.4 | 0.0 | 0.0 | 0.4 | 0.0 | 0.6 | 23.6 | 0.8 | 4.1 | 0.1 | 0.0 | 0.1 |
| OCT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 7.3 | 7.8 | 0.0 | 1.6 | 1.2 | 1.0 | 0.1 | 0.0 | 0.4 | 0.0 | 0.3 | 21.0 | 1.2 | 4.0 | 0.2 | 0.0 | 0.0 |
| NOV | 0.0 | 0.1 | 0.1 | 0.7 | 0.0 | 0.3 | 7.3 | 7.6 | 0.1 | 1.5 | 0.9 | 1.5 | 0.2 | 0.1 | 0.9 | 0.0 | 1.0 | 18.3 | 1.4 | 3.7 | 0.1 | 0.0 | 0.0 |
| DEC | 0.0 | 0.0 | 0.0 | 2.0 | 0.0 | 0.4 | 5.3 | 5.7 | 0.0 | 1.1 | 1.7 | 1.0 | 0.4 | 0.0 | 1.6 | 0.0 | 1.9 | 12.8 | 2.3 | 4.7 | 0.3 | 0.0 | 0.0 |


Increased prevalence of viruses: **Rhinovirus, RSV, Boca virus, Parainfluenza 2,3,4, Adeno, Flu A**




ACL RSV positivity rate - trends down

CDC Data RSV pos rate for Region 5 Chicago - (PCR – 7%↓, Antigen - 9% ↓)

Total PCR Tests




Total Antigen Tests



CDC RSV positivity rate - trends down


| SARS-COV-2 | | | | | Influenza PCR | | RSV PCR | |
|------------|-------------|-------------|------------|------------|---------------|-------------|-------------|-------------|
| Week | IL % SCVPCR | WI % SCVPCR | IL % COVAG | WI % COVAG | IL % FLUPCR | WI % FLUPCR | IL % RSVPCR | WI % RSVPCR |
| Dec 12 | 12.2 | 8.5 | 14.7 | 20.6 | 5.1 | 7.1 | 5.3 | 4.0 |
| Dec 5 | 11.1 | 11.3 | 13.5 | 22.7 | 5.5 | 5.5 | 5.1 | 6.0 |
| Nov 28 | 8.8 | 10.6 | 12.8 | 18.9 | 3.9 | 1.8 | 10.2 | 9.8 |
| Nov 21 | 5.8 | 10.3 | 8.5 | 20.2 | 1.9 | 0.2 | 14.0 | 12.0 |
| Nov 14 | 4.7 | 9.0 | 7.5 | 21.7 | 0.5 | 0 | 15.0 | 15.7 |
| Nov 7 | 3.8 | 7.4 | 6.6 | 17.6 | 0 | 0.3 | 21.4 | 20.7 |
| Oct 31 | 3.8 | 6.3 | 4.8 | 13.7 | 0.3 | 0 | 20.9 | 32.2 |
| Oct 24 | 3.7 | 5.6 | 5.1 | 16.7 | 0 | 0.2 | 22.5 | 30.6 |
| Oct 17 | 3.7 | 6.5 | 7.0 | 18.0 | 0 | 0 | 27.0 | 31.3 |
| Oct 10 | 4.3 | 7.6 | 5.0 | 18.2 | 0 | 0.2 | 23.9 | 32.6 |
| Oct 3 | 5.0 | 8.6 | 6.0 | 16.6 | 0 | 0 | 24.9 | 35.5 |

ACL SARS-CoV-2 and Flu PCR positivity rate - **trends up**




ACL SARS-CoV-2 positivity rate - trends up

CDC- Daily COVID-19 cases in US – Dec 8, 2021



CDC SARS-CoV-2 positivity rate - trends up

Dec 11, 2021 – SARS-CoV-2 circulating in the US (96.7% Delta ↓, 3% Omicron ↑)



US vaccination status CDC |Data as of: Dec 8, 2021

477,433,765

Vaccines Administered

237,468,725

People who received at
least one dose

200,717,387

People who are fully
vaccinated*

71.5%


Percentage of the U.S.
population that has
received at least one
dose


60.5%

Percentage of the U.S.
population that has
been fully vaccinated*

US vaccination vs hospitalization status CDC | Data as of: Dec 8, 2021


Age-Adjusted Rates of COVID-19-Associated Hospitalizations by Vaccine Status in Adults Aged ≥ 18 Years, January–October 2021






ACL Flu positivity rate – trends up (133 pos/2256 samples tested)

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, October 3, 2021 – December 4, 2021




CDC Flu positivity rate – trends up 2.6%


CDC Midwest data as of: Dec 4, 2021




2021-22 Influenza Season Week 48 ending Dec 04, 2021



CSF targets positivity rate is 2.5%



The most prevalent GI bacterial target is - (Salmonella 1.0%)



The most prevalent GI viral target are – (Adeno, Noro – 0.4%)

ACL GPP - STOOL POSITIVE VIRAL TARGETS - Dec 12, 2021

